11 Analysts Have This to Say About Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have rated Regeneron Pharmaceuticals (NASDAQ:REGN) with 2 bullish, 4 somewhat bullish, and 5 indifferent ratings in the last quarter. The average price target is $888.45, representing an upside from the current price of $795.94. The target has increased by 3.36% over the past month.

November 28, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given Regeneron Pharmaceuticals positive ratings with an average price target of $888.45, indicating an upside from the current price of $795.94.
The consensus among analysts suggests optimism towards REGN, with a higher average price target than the current price. This positive sentiment, especially with no bearish ratings, could lead to a short-term increase in the stock price as investors may be influenced by the expert opinions and the implied upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100